Pharma Journalist

2nd Annual RAS – Targeted Drug Development – Digital Summit
2020-09-14 - 2020-09-16 | Digital Event
Via the latest data driven case studies from academic and industry pioneers, the 2nd RAS Targeted Drug Development Summit (running digitally this year!) will shine a spotlight on optimizing the selectivity and tolerability of your anti-RAS therapies, exploring novel combination strategies and overcome translational pharmacology challenges to set the stage for the 2nd generation of mutation-targeted RAS modulating therapies yet to come.

Explore how to leverage the internal structural biology of RAS mutations in order to produce effective and clinically viable therapies with discussions from E Shaw Research, The Johns Hopkins University School of Medicine & Hospital for Sick Children
Deep dive into RAS associated pathways in order to optimize combination therapies with insights from Novartis, Genentech & Deciphera Oncology
Evaluate the mechanisms of action and resistance of RAS targets to accelerate target validation and clinical translation with insights fromAbbvie, PhoreMost & Verastem Oncology
Adopt novel techniques to successfully target therapeutic vulnerabilities in RAS-driven cancers with lessons learnt from BeiGene, Genentech, Revolution Medicines, Oblique Therapeutics & Aro Biotherapeutics
Explore the successes and future therapeutic potential of targeting mutation beyond G12C from within the RAS community explored Revolution Medicines, Francis Crick Institute & MD Anderson Cancer Centre

Following the success of RAS-Targeted Drug Discovery Summit in 2019, we will re-unite the RAS community virtually this coming September with the most comprehensive and definitive conference specifically dedicated to this community.
Join 250+ of the leading minds from large pharma, biotech and academia across the globe who are striving to capitalise on the therapeutic opportunity of targeting RAS through advancing novel mechanisms of action, improving drug-like properties and accelerating the translation of potent and mutation-targeted 2nd generation RAS targeted therapeutic strategies into human clinical trials.

TIDES: Oligonucleotide & Peptide Therapeutics 2020
2020-09-15 - 2020-09-18 | 100% Virtual
The #1 event for oligonucleotide, peptide, CRISPR and mRNA therapeutic leaders. Join us for top-notch networking, high-level industry expert speakers, innovative company presentations, interactive scientific poster presentations, and diverse attendee companies and investors — in a multi-day digital format that you can access from anywhere in the world.

11th World Bispecific Summit – Running Virtually for 2020
2020-09-22 - 2020-09-24 | Virtual Summit
Transforming to a digital platform for the eleventh year, the World Bispecific Summit will continue to deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery, translational and manufacturing challenges faced in the bispecific field. Whatever your role and interest in the field, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients.

Discover who the 40+ expert speakers are, and the topics they will examine, including how:

MacroGenics are evaluating selection and format optimization of bispecific molecules for a simultaneous blockade of PD-1 and LAG-3 (MGD013) versus PD-1 and CTLA4 (MGD019)
Sound Biologics are pioneering their unique platform, MabPair Technology for making bi-functional antibody
Invenra demonstrates preclinical efficacy through the selective elimination of tumor Tregs
Incyte and Adimab are enhancing the selectivity of bispecific approaches to reduce on-target off-tumor toxicities in solid tumor indications
Genentech are showcasing how several factors such as epitope, binding affinity, format, target expression, etc., influence the design and development of T-cell bispecific for cancer immunotherapy

Download the event guide to find out more

TIGIT Therapies Digital Consortium
2020-09-24, 2020-10-27 | Online
Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies.
Following the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications, a great deal of momentum has built in this competitive space.

However, core challenges must still be addressed by the community, such as:

Investigating the TIGIT pathway, ligands, and modes of action
Optimizing biomarker strategy to identify optimal patient populations and indications
Rationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit

The TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event.
In such a fast-paced industry, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact.
Working with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies.
At a time when we are more isolated than ever, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies.
Head to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!

2nd European Protein Degradation Congress
2020-09-28 - 2020-09-29 | Virtual Event
With deals in the protein degradation market reaching nearly $2 billion and unique degradation ideas coming into play such as LYTACs and ENDTACs, eyes are focused on how much further protein degradation-based therapeutics will continue to grow within the pharmaceutical industry.
Following huge success in May 2019, the 2nd European Protein Degradation Congress, returns on 28th – 29th September 2020, where you can hear the most up to date and relevant information for the broad range of topics in the field of targeted protein degradation.

New areas will cover novel methods in harnessing E3 ligases and the latest discoveries from PROTACs and molecular glues with preclinical and clinical data being shown.
Leading industry players from biotechs and big pharma will come together to exchange thoughts on how to best overcome obstacles to achieving reliable in vitro and in vivo data. Academic experts will be present their latest research to help build a deeper understanding of the mechanisms involved in the Ubiquitin pathway, providing a clearer picture on what makes a good, or not good, target for degradation.
To know more about 2nd European Protein Degradation Congress please click here.

Gene Therapy for Inherited Metabolic Disorders
2020-09-30 | Online
The inaugural Gene Therapy for Inherited Metabolic Disorders Summit will put the spotlight on the understanding of topics from the physiopathology of disease through to the nuances of dosing and delivery methods and designing a trial with endpoints and outcome measures that are meaningful both clinically and to patients.

Join 60+ industry leaders across the metabolic disorders space to overcome the specific delivery and drug development challenges to accelerate the development of more clinically efficacious, durable and safe gene therapies for metabolic disorders.
Don’t miss this opportunity to join pioneers from AstraZeneca, Amicus Therapeutics and Rocket Pharmaceuticals on this journey to revolutionize the treatment of inherited metabolic disorders.
To know more about Gene Therapy for Inherited Metabolic Disorders please click here.

Gamma Delta T Therapies Summit
2020-09-30 | Digital Event
Accelerating the Development of Gamma Delta T Therapies in Oncology
Join us on Wednesday, September 30, to discuss the precise mechanisms of γδT cells, examine donor selection for allogeneic therapies, and deliberate the targeting of solid tumours.
As we virtually gather world-leading researchers at the Gamma Delta T Therapies Summit, learn how the industry is effectively manipulating and engineering gamma delta cells with antibody and cell-based approaches for improved safety, efficacy and manufacturability to bring to market effective Gamma Delta Therapies for patients in need.
With a unique opportunity to pose questions to experts and gain fresh insights on such a fast paced and growing field in a live Q&A, this digital event is not to be missed.
Find out more about the event and to see participation opportunities: https://ter.li/qk6gc1

5th Annual PREDiCT: 3D Oncology & Tissue Models
2020-09-30 - 2020-10-01 | Digital Event
The Digital 5th PREDiCT: 3D Oncology & Tissue Models Summit will return this September, with defined tracks and a fresh speaker line-up, bringing together preclinical scientists to discuss adoption and commercialization of 3D models as an integral part of drug development study.
This event is completely free for Drug Developers, Researchers and Academics. To register your complimentary pass, simply follow this link: www.3d-oncology-tissuemodels.com/take-part/register/.
This fully online meeting will feature over 30+ senior Preclinical Scientists from oncology to cardiovascular to musculoskeletal and CNS backgrounds, to share their latest data and lessons learned from clinically translatable 3D models to disease modeling of mechanisms, to attempting complex multi-cellular/organ systems to boost our understanding of functionality and physiological relevancy.
Embark on the 3D trailblazing community to boost your confidence in 3D models and accelerate bench to bedside drug development to provide a truly safe, and effective treatment for patients!
Access your copy of the Full Event Guide here.

The 5th Computational Drug Discovery & Development (CDD) for Biologics Summit
2020-10-06 - 2020-10-08 | Virtual Event
Built with insights from the likes of AbbVie, Sanofi, Amgen and Takeda; CDD for Biologics Summit has been specifically designed to help biopharma companies define strategies to further adapt computational tools, mitigate data availability issues and address computational-experimental challenges to add immediate value to their biologics pipelines.
This dedicated platform will enable you to address key challenges such as those of widespread data sharing, the experimental constraints of generating enough data and the importance of overcoming data silo-ing with organizations, as well as exploring new opportunities including a novel, AI-derived approach, an automated high-throughput engineering platform, successfully deploying ML algorithms and more.
Across 3 days online, 24 experts will share in-depth their findings on:
• Leveraging machine learning and computational programs to discover, design and develop de novo antibodies
• Model and design structure-based antibody and T cell receptor recognition
• Computational design of antibodies against spike epitopes of SARS-CoV-2
• Plug and play application and advantages of computational design
• Deep dives into computational modeling of immunogenicity prediction, validation; and opportunities for data availability and sharing
Join a diverse faculty of experts this October for the 5th annual gathering to uncover progress made, and how we can accelerate the adoption of computational tools in the discovery and development of biologics.
To know more about CDD for Biologics Summit please click here.

Pulsed x-ray technology & smart optics for a total inspection of pre-fillable syringe cannulas and needle shields
2020-10-07 | Virtual Webinar
HOSTED BY: HEUFT
LED BY: DAN MCKEE
General Manager, HEUFT USA Inc
Dan McKee is the General Manager of HEUFT USA. He has spent 25 years working with high-speed quality control inspection equipment in the packaging industry. In doing so, he’s become well versed in non-destructive techniques for testing a wide variety of package attributes using technologies as diverse as x-ray imaging, capacitive gauging, inductive profiling, and various vision techniques. His responsibilities have included commissioning inspection devices within a wide variety of production environments, specifying devices to satisfy customers’ application conditions and working with R&D to customize equipment to conform to his customers’ unique challenges. Dan now leads HEUFT’s sales and service organization for the United States and Canada.
Dan Received his BSEE from the Illinois Institute of Technology in 1993, and a Master of Engineering Management (MEM) in 2001 from Northwestern University.

LED BY: RONALD TURN
Pharmaceutical Sales Engineer, HEUFT USA Inc
Ronald Turn joined Heuft USA in 2019 as the Pharmaceutical Sales Representative. Ron has spent the past 10 years in a technical sales roll selling different varieties of Capital Analytical Research Instrumentation to the Pharmaceutical, Biotech, Chemistry, and Life Sciences industries. Ron also has worked for two major Pharmaceutical companies as an Analytical Chemist. With the combination of sales experience and Scientific knowledge, Ron is responsible for everything related to the Pharmaceutical portfolio offered by Heuft USA.
Ron Received his bachelor’s degree in Chemistry from Western Illinois University in 2008.
Webniar overview:
The pulsed X-ray detection module from HEUFT identifies numerous safety and integrity defects of pre-fillable syringes after the caps have been applied with unrivaled low radiation. The HEUFT Syringer detects non-conformities that would normally be invisible to a camera system such as needle shields (both SNS & RNS) pierced by the hypodermic needle, deformed cannulas or incorrectly assembled, defective or leaking luer-lock screw adapters and tamper evident closures of disposable syringes.
The compact detection unit can be enhanced with innovative smart optics for detecting needle hooks which complement the unique pulsed X-ray technology for a careful and precise pre-fillable syringe inspection. An intelligent color sensor camera, developed by HEUFT, examines the tiny needle tips from above before the protective covers have been added. The special light dispersion of the adaptive LED lighting used for this purpose ensures that even the smallest faults become visible.
The HEUFT Syringer is extremely compact and very easy to integrate into packaging machines for such pre-fillable injection instruments.
During this Webinar, Information will be shared about the Heuft Syringer such as design features, functionality, implementation, and benefits of using the HEUFT Syringer to assure only quality pre-filled syringes reach the market.
WHO SHOULD ATTEND?

Quality Managers
Heads of Quality
Manufacturing/Operations Managers
Heads of Manufacturing/Operations
Heads of Fill-Finish
Fill-Finish Manager
R&D scientists
Formulation scientists
CMC regulatory
Packaging engineers
Engineers and Managers in Device Development and all other technical functions surrounding syringe systems
Clinical and commercial Drug Product Manufacturing
Formulation scientists
Laboratory scientific staff and managers
Parenteral manufacturing staff
Sterility Quality Assurance
Regulatory affairs scientists
Pharmaceutical packaging component manufacturing staff

For more information and to register your free place, visit:
https://www.smi-online.co.uk/pharmaceuticals/webinar/pfs-cannulas-and-shields
Additional Contact Information
Jinna Sidhu – Marketing Manager
Pharmaceutical Division – SMi Group Ltd
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk

2nd Flow Cytometry Congress
2020-10-08 - 2020-10-09 | London, UK
As a vital tool for providing quantifiable data on cell characteristics, flow cytometry is an integral part of diagnostics and the assessment of therapeutic efficacy. Talks will also explore the application of flow cytometry in disease monitoring and diagnosis, and approaches to implementation in the clinic.

The meeting will focus on:

Advances in flow cell and sheath fluid design.
The development of new fluorophores.
Next-generation detection systems, and
An applications session exploring the analysis of cell surface antigens, reviewing cell health, cell sorting techniques and
The role of flow cytometry in drug development.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field.
Delegates will also have access to the co-located Liquid Biopsies Congress and qPCR and Digital PCR Congress.
Visit the event page to download the full agenda.

7th QPCR & Digital PCR Congress
2020-10-08 - 2020-10-09 | London, UK
qPCR & Digital PCR are the most essential techniques used for quantification of nucleic acid molecules in molecular biology and diagnostics.
Where qPCR is considered as a powerful technique that can provide precise and quantitative data reflecting the biology of the tested experimental parameters, the excellent precision of dPCR supports its application for the detection of rare point mutations and mutations induced by gene editing in a background of wild-type sequences.

At this congress our expert speaker panel will address these challenges in the form of case studies and interactive sessions. The agenda will focus on the challenges which need to be addressed to successful move forward into clinical studies:

Accuracy
Reproducibility
Assay optimization
Multiplexing
Standardization
Translating methods into applications

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field.
Delegates will also have access to the co-located Flow Cytometry Congress and Liquid Biopsies Congress.
Visit the event page to download the full agenda.

2nd Liquid Biopsies Congress
2020-10-08 - 2020-10-09 | London, UK
This conference offers experts working in the biopharmaceutical industry as well as academia the opportunity to examine the latest developments in the field with dedicated congress presentations, panel discussions and roundtables.

The agenda will explore :

Novel methods, research techniques, advances and discoveries in the field.
Research applications utilizing technologies such as qPCR, Digital PCR and NGS.
The detection and analysis of on circulating biomarkers such as cell-free DNA, (cfDNA), circulation tumor cells (CTCs), and extracellular vesicles (EVs).
The growing field of single cell analysis and he use of different fluids for non-invasive testing.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships. This meeting will allow you to keep up to date with the cutting edge of research and the opportunity to further business partnerships with those in your field.
Delegates will also have access to the co-located Flow Cytometry Congress and qPCR & Digital PCR Congress.
Visit the event page to download the full agenda.

Animal Health Investment USA
2020-10-12 - 2020-10-13 | Venue tbc, Boston, MA, United States
Animal Health Investment USA is a premier investment forum showcasing the most exciting partner opportunities in animal health and connecting those businesses together with financial investors and strategic corporate partners.

Once again, our forum in Boston will be split into two tracks, a human biotech and animal health partnering track and an investor track. The first will be looking specifically at maximizing the therapeutic and commercial potential of human technologies and serving unmet medical needs in veterinary health, the second will be focused on driving investor engagement and showcasing the industry’s most exciting emerging companies.
We will include keynote presentations and host C-level panel discussions that address the trends and market dynamics of the animal health industry, across all species. A key element of the investment forum is the full use of a our 1-on-1 meeting scheduler, available to all attendees.
To know more about Animal Health Investment USA please click here.

3rd Targeted Protein Degradation Summit
2020-10-13 - 2020-10-15 | Digital Event – EDT
Off the back of the newly released first-in-human data utilizing PROTACs, it is more than ever evident that the field of targeted protein degradation is redefining the therapeutic landscape across the whole of the pharmaceutical industry. Despite the recent success, significant challenges are continuing to hold back the progress of the discovery and development of safe and effective protein degraders.
For the 3rd time, the TPD Summit is providing you with the leading platform that showcases the latest developments and advancements in the field, bringing together the leading biopharmaceutical and academic organizations in an intimate networking environment to focus on successfully degrading intracellular & extracellular targets, improving rational design and accelerating the translation of next generation proteasomal- & autophagy- mediated protein degraders into clinical trials.
Here is a sneak peak of just some of our 60+ world-class speaker faculty:

Jay Bradner, President, Novartis Institutes for Biomedical Research
Craig Crews, John C. Malone Professor of MCDB, Chemistry & Pharmacology, Yale University
Alessio Ciulli, Professor of Chemical & Structural Biology, University of Dundee
Matt Disney, Professor of Chemistry & Neuroscience, Scripps Research
Ian Churcher, Chief Scientific Officer, Amphista Therapeutics
John Houston, President & Chief Executive Officer, Arvinas
Ray Deshaies, Senior Vice President of Global Research, Amgen
Nello Mainolfi, Founder, President & Chief Executive Officer, Kymera Therapeutics
Stewart Fisher, Chief Scientific Officer, C4 Therapeutics
Scott Edmondson, Director & Head of Boston Oncology Chemistry, AstraZeneca
Yu Shen, Director of Cancer Biology, AbbVie
Richard Glynne, Chief Scientific Officer, Lycia Therapeutics
Ingrid Wertz, Principal Scientist & Project Team Lead, Genentech

Don’t miss the most comprehensive, industry-focused meeting in the field specifically dedicated to the discovery and development of targeted protein degradation strategies to advance your pipelines towards success!

8th Plant Genomics & Gene Editing Congress: USA
2020-10-19 - 2020-10-20 | Raleigh-Durham, USA
The Congress will explore novel strategies and developments in plant genomics and gene editing through a series of case studies and an examination of the latest scientific research. Leaders from academia and industry will consider key developments in gene editing technologies such as CRISPR/Cas9 and TALEN and discuss its application in improving disease resistance, stress tolerance and crop yield.

Discover how research institutions and agri-biotech are using gene-editing technologies to advance their research.
Learn how to apply successful bioinformatic strategies to overcome plant phenotyping challenges.
Explore the impact of gene editing regulation.
Building on existing partnerships and creating new collaborations across industry & academia

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

5th Partnerships in Biocontrol & Biostimulants Congress: USA
2020-10-19 - 2020-10-20 | Raleigh-Durham, USA
Case studies across the two days will examine developments in biopesticides and biostimulants and the application of new research in increasing crop yield, improving soil health & nutrient uptake, and efficient water use. Experts from industry and academia will also discuss pest management strategies and provide regulatory updates in the field.

Discover how research institutions and agri-biotech are developing the next generation of bacterial biostimulants.
Learn how to apply successful bioinformatic strategies to advance your research.
Explore the updated understanding of biopesticides and biostimulants regulation.
Hear about insights into the role of plant and soil microbiomes.
Build on existing partnerships and create new collaborations across industry & academia.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Microbiome for Agriculture Congress: USA
2020-10-19 - 2020-10-20 | Raleigh-Durham, USA
The meeting will examine the symbiotic relationships between microbes and plants through case studies in plant and soil microbiomes. Academic and industry leaders will discuss new research into the rhizosphere, phyllosphere and endosphere and the application of plant and soil microbiome research in improving disease resistance, nutrient acquisition and crop yield, and tolerance to multiple stressors including nematodes, insects and drought.
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

5th Microbiome Movement – Drug Development Summit
2020-10-19 - 2020-10-21 | Digital Event – EDT
The 5th Microbiome Movement – Drug Development Summit (October 19-21, Digital Event – EDT) continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical, biotech and academic community pursue the causal role of the human microbiome in disease, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs.

With over 60 speakers taking part, the four focus areas for 2020 include:

Pre-Clinical Development & Mechanisms of Microbiome-based Therapeutics
Learn how industry and academic pioneers are developing novel microbiome platforms to identify new targets and therapeutics across a range of microbiome-targeting modalities and disease phenotypes
Clinical Development, Manufacturing & Commercialization of Live Biotherapeutics
As the industry prepares for pivotal clinical readouts this summer, this year’s discussion will give you the knowledge and insight required to navigate through the specific translational, clinical and manufacturing challenges for live biotherapeutics
Microbiome-based Biomarkers, Diagnostics & Patient Stratification
Mine the human microbiome to discover new biomarkers of disease and help predict response, understand drug metabolism and develop non-invasive diagnostic tools
Applications in Oncology
Gain a comprehensive insight into the most exciting disease target in microbiome research today with case-studies and discussion from leading cancer researchers, oncology-specific clinicians and the pharmaceutical industry

If you are, or would like to be, a player in the microbiome arena, this is the conference you should attend to not only hear the latest pre-clinical and clinical development from organizations developing microbiome-based therapeutics, biomarkers and diagnostics, but also to make long-lasting connections that will accelerate your microbiome developments forward, and help translate this promising science into a reality for patients.

Outsourcing in Clinical Trials Nordics 2020
2020-10-20 - 2020-10-21 | Virtual Event
After the challenges of 2020 with the Covid-19 pandemic, this is the unmissable event that the pharmaceutical,
biotechnology, and medical device communities need to come together and discuss strategies for operational success in clinical trials. With all the latest content, and a big focus on the latest regulations and technology, the conference will offer an unparalleled opportunity to hear in-depth talks from the likes of the Danish Medicines Agency, LEO Pharma, and TÜV SÜD, as well as C-level and senior experts from the Nordic region.

To know more about Outsourcing in Clinical Trials Nordics 2020 please click here.

Pre-Filled Syringes East Coast 2020
2020-10-26 - 2020-10-27 | Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States
SMi are proud to announce the 7th annual conference:
Pre-Filled Syringes East Coast 2020
26-27 October 2020
Boston, USA
Sheraton Boston Hotel
http://www.pfsamericas.com/pjwl
Innovations in parenteral device and product development

SMi Group are proud to announce the 7th Pre-Filled Syringes East Coast conference returning to Boston, USA on 26th-27th October 2020.
The global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry, is expected to exceed $9.7 billion by 2025. With that in mind, for its 7th year running- the 2020 event will aim to focus on new trends on digital technology advancements, human studies and innovative design and delivery systems within the prefilled syringe industry.
Themes for 2020:
Pre-Filled Syringes East Coast 2020 will be exploring themes of Container Closure Interaction and Formulation; On-body Injectors; Digital connectivity in the parenteral space; A regulatory outlook with industry and recognised body experts; Patient centricity and device development; Developments in device technology; Parenteral gene therapy and New for 2020: PFS Interactive Workshop Day.
This comprehensive overview will help attendees understand the changing global market and the challenges faced within the industry.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more..
Key Reasons to Attend:

EXPLORE the latest case studies parenteral drug delivery
GAIN insights into the use of pre-filled syringes for gene therapy
NETWORK with leading industry experts, key opinion leaders and regulatory body representatives
ENGAGE in the key challenges and topics of the field in the interactive post-conference workshop day

Who should attend:

Drug-delivery developers
Medical Device Engineers
Primary Packaging material designers
Secondary packagers
Smart device developers
Training device developers
Device-safety solution providers
Drug developers

To register or for more information visit: www.pfsamericas.com/pjwl
SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #Smipfsusa
LinkedIn: follow our company page – search ‘SMi Pharma’

Smithers’ Extractables and Leachables USA 2020
2020-10-26 - 2020-10-28 | Virtual Event
Smithers’ 9th annual Extractables and Leachables USA conference is returning. This is a unique event in the extractables and leachables industry, bringing together top companies from the entire supply chain and making it easy to network with peers, leading to new, beneficial connections. The event is a must for the extractables and leachables industry, wherein players need to stay on top of market changes, fluctuating regulations, medical device strategies, and safety standards for consumer safety and product success. Smithers’ E&L 2020 gathers industry experts to discuss these topics, and more. The program consists of two days of industry-leading presentations by over 20 expert speakers, supplemented by valuable networking breaks, an included networking lunch, and a networking reception at the end of day one.
Companies who have attended in the past include B Braun, The FDA, Toxikon, Intertek, Abbott, Nelson Laboratories, Boston Scientific, Vimta, Jordi Labs, VR Analytical, Teknor Apex, and many more.
Visit the event website for more information: https://www.eandl-conference.com/usa.
Contact Producer Ashli Speed, ASpeed@Smithers.com, with questions about the program.
For companies interested in increasing their brand visibility in front of a target market, contact Shannon Siegferth, SSiegferth@Smithers.com, about sponsorship opportunities.
To get the latest updates, follow the event on twitter @SmithersELEvent, join the LinkedIn group Extractables and Leachables Forum, or join the mailing list: https://www.eandl-conference.com/usa/register-interest.

TIGIT Therapies Digital Summit
2020-10-26 - 2020-10-27 | Online
Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies.
Following the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications, a great deal of momentum has built in this competitive space.

However, core challenges must still be addressed by the community, such as:

Investigating the TIGIT pathway, ligands, and modes of action
Optimizing biomarker strategy to identify optimal patient populations and indications
Rationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit

The TIGIT Therapies Digital Summit will gather the greatest minds in TIGIT research in a dedicated, two day meeting. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings for your future research.
In such a fast-paced industry, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact.
Working with leaders in the industry we have developed a meeting that brings together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies.
At a time when we are more isolated than ever, this event will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies.
Head to the TIGIT Therapies Digital Summit website to access your complimentary event guide and find out more!

4th Annual Gene Therapy for Rare Disorders Europe | Running Digitally for 2020
2020-10-26 - 2020-10-28 | Virtual Event
Realise the Commercial Potential of Gene Therapies
The 4th Annual Gene Therapy for Rare Disorders Europe is dedicated to overcoming
manufacturing, clinical, and commercialisation challenges drug developers face when delivering
gene therapies to market.
With new European gene therapy approvals rapidly approaching and investment at an all-time high, the digital meeting will leverage the experience from the first to market pioneers, as well as unveiling the strategies the next generation of drug developers are employing to improve efficacy, safety and commercial viability.

Across three days, we will virtually unite 250+ leading experts from innovative biotechs, large pharmaceutical companies, academia, and key service providers. Understand the nuances of the European regulatory landscape, engage with European payers and ensure your manufacturing and logistical approaches are set for the commercial primetime to come.
Wherever you’re based, if you’re looking to develop and launch gene therapy products in Europe, this is your comprehensive guide to define your commercial path forward
To learn more about Gene Therapy for Rare Disorders Europe please click here: https://ter.li/k19u77

Macrophage-directed Therapies Summit 2020
2020-10-27 - 2020-10-29 | Virtual Event
Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond
With the explosive excitement and clinical proof of concepts utilizing CD47 approaches, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47.

The 2nd Macrophage-directed Therapies Summit is focused on optimizing the potential of macrophage therapies, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond.
Bringing together the leading experts, we will explore the clinical development of CD47 checkpoint blockades, combination strategies, macrophage repolarization approaches and engineered macrophages.
Join the trailblazers of macrophage therapeutic development, from the likes of Carisma Therapeutics, Faron Pharmaceuticals, and Verseau Therapeutic, as we come together to advance the fundamental understanding of macrophage biology, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.

Pharmaceutical Microbiology East Coast
2020-10-28 - 2020-10-29 | Virtual Event
SMi’s 3rd Annual Pharmaceutical Microbiology East Coast
Conference: 28 – 29 October 2020
Location: Virtual Event
Website: www.microbiologyeastcoast.com/PJWL
SPONSORED BY: Associates of Cape Cod, bioMérieux, Bioscience International, C.T.L. MAT, LONZA
CHAIRED BY: Lynne Ensor,VP Technical, Parexel
Exploring the current approaches towards improved contamination control
The pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods, revisions being made to regulations in the industry, enhanced knowledge of the human microbiome, and novel testing methods, this industry is ever expanding.
Join industry experts to discuss and analyze the latest advances and challenges within the industry. Network with industry professionals, discuss the revision of Annex 1, explore data integrity considerations for conventional and rapid microbiology methods, analyze arising issues with environmental monitoring and gain insight into an industry perspective on automated endotoxin testing and process automation.
Event Hashtag: #SMiPharmaMicroEC
HIGHLIGHTS FOR 2020:

Discuss ongoing complication of personnel derived contaminations from the FDA
Gain valuable insight towards microbiological quality considerations in non-sterile manufacturing and control of BCC from Parexel
Learn from the perspective of the US Pharmacopeia on container closure integrity evaluation
Examine an end-to-end contamination risk assessment for autologous cell therapy from Juno Therapeutics
Explore a back to back Genentech session covering technical considerations for microbial QC of raw materials used in biotechnology and the past, current and future state of Mycoplasma testing

The Use of Recombinant Chromogenic Assays as Alternate Methods for the Bacterial Endotoxins Test (BET)
Workshop Leader:
Veronika Wills, Manager, Technical Services, Associates of Cape Cod
View the full agenda: www.microbiologyeastcoast.com/PJWL
WHO SHOULD ATTEND
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist, Drug Substance External Manufacturer, QC Scientists, Heads of Quality, Business Development Manager, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist
To know more about Pharmaceutical Microbiology East Coast please click here.

Dry AMD Therapeutic Development Summit
2020-10-28 - 2020-10-29 | Virtual Event
Finding new therapeutics to counter the progression of Dry AMD and prevent the geographical atrophy has never been more important. The aging population creates an ever-growing clinical need for next-generation therapeutics.
This action-packed two-day digital agenda holds 22 Presentations from industry and academic leaders, a virtual poster session and 5+ hours of networking, you can join the only platform discussing issues present in the development of Dry AMD therapeutics.

Join this critical global forum which will be uniting industry specialists from pharma, biotechs, academia and solution providers as we target the most pressing issues important to bringing the next generation of Dry AMD drugs to market.
Companies speaking include: Genentech, 4D Molecular Therapeutics, Alkeus Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, University of California, San Francisco, Regenerative Patch Technologies, Novartis, Stealth BioTherapeutics Inc
Find out more here > https://ter.li/mc1pmz

Patient-to-Patient Supply for Cell Immunotherapies Summit
2020-10-29 - 2020-10-30 | Digital Event
Achieving Standardization & Operational Excellence in Vein-to-Vein Supply
As an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment, cell therapies pose unique supply chain challenges.

At the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit, this community will share their expertise and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale.
From time and temperature sensitivity, to patient-facing service and integrated platforms, a seamless vein-to-vein supply chain is central in maintaining cell immunotherapy safety and efficacy at scale and maximizing the patient experience.
Join the strategic experts from GSK, bluebird bio, Adaptimmune, Celgene, BMS and more, to discuss best practice for patient-facing supply chains and build integrated platforms for chain of identity and end-user access.

Digital 5th Neoantigen Based Therapies Summit
2020-11-03 - 2020-11-05 | Online | Digital Event
With all eyes on the explosive neoantigen field watching to see how it can revolutionize cancer immunotherapies and rival the current T cell therapies, it is clear that critical questions still remain to be addressed to ensure full therapeutic success.

Taking place from the comfort of your own home this year, the 5th Neoantigen Based Therapies Summit remains the only industry focused meeting dedicated to the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies.
View the full event guide for more details on this content packed 3-day virtual event.
We’ll be addressing the most pressing challenges in the field, including:

Identifying both personalized and shared Neoantigens to supercharge development of next generation immunotherapy with University of Miami and Netherlands Cancer Institute
Improving prediction accuracy by exploring different neoantigen sources with Ervaxx, Precision Biologics and Broad Institute
How to maximize immunogenicity to drive clinical development & success with Gritstone Oncology, Genocea and Treos Bio
Reducing complex process and release times by navigating through complex manufacturing challenges with Achilles Therapeutics, Vaximm and ISA Therapeutics

Download the official brochure to see what sessions will help you to advance your cancer immunotherapy pipeline.
Join us online to gain the practical insights you need to improve the immune response and commercial viability of your neoantigen based cancer immunotherapy.
